文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

赴美难民免疫规划:2012年至今的发展、挑战与机遇

An immunization program for US-bound refugees: Development, challenges, and opportunities 2012-present.
PubMed 文献 · Vaccine · 2020-11-18

美国疾控中心与国务院合作,自2012年起为赴美难民实施海外免疫规划。至2019年9月,规划覆盖五大洲80余国,近32万受检难民有至少1剂疫苗记录;2019财年95%抵达难民有至少1剂含麻疹疫苗记录。规划使难民团组因疫苗可预防疾病取消旅行的情况从每年2-8次降至2015-2019年仅2次。

要点

  • 赴美难民海外健康评估不要求免疫,CDC与国务院2012年起合作实施全球免疫规划。
  • 规划实施后疫苗可预防疾病相关团组旅行取消从每年2-8次降至2015-2019年仅2次。

核心结论

  • 赴美难民海外免疫规划成功实施,因减少旅行取消、降低海外免疫成本及可能减少疫苗可预防疾病发病率,预计可节省大量成本。

研究设计与样本

  • 描述性规划报告,介绍赴美难民疫苗接种计划的制定、实施与挑战应对,并估算2019年免疫覆盖率及乙肝感染患病率。

主要发现

  • 至2019年9月,规划在五大洲80余国活跃,近32万受检难民有至少1剂疫苗记录。
  • 2019联邦财年,95%抵达难民有至少1剂含麻疹疫苗记录。
  • 2015-2019年仅2次疫苗可预防疾病相关难民团组旅行取消,规划前每年2-8次。

关键数值与推荐

  • 2019年免疫覆盖率估算基于海外健康评估期间接受至少1剂含麻疹疫苗的年龄合格难民人数。
  • 乙肝感染患病率基于乙肝表面抗原检测结果计算。

临床怎么用

  • 为赴美难民在海外健康评估时提供免疫接种,可减少疫苗可预防疾病相关旅行取消。
  • 维持统一标准需引入专职人员、制定规划专用方案并持续提供技术支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: US-bound refugees undergo required health assessments overseas to identify and treat communicable diseases of public health significance-such as pulmonary tuberculosis-before migration. Immunizations are not required, leaving refugees at risk for vaccine-preventable diseases. In response, the US Centers for Disease Control and Prevention and the US Department of State developed and co-funded a global immunization program for US-bound refugees, implemented in 2012 in collaboration with the International Organization for Migration. METHODS: We describe the Vaccination Program for US-bound Refugees, including vaccination schedule development, program implementation and procedures, and responses to challenges. We estimate 2019 immunization coverage rates using the number of age-eligible refugees who received ≥1 dose of measles-containing vaccine during overseas health assessment, and calculated hepatitis B infection prevalence using hepatitis B surface antigen testing results. We report descriptive data on adverse events following immunization. RESULTS: By September 2019, the program was active in >80 countries on five continents. Nearly 320,000 examined refugees had ≥1 documented vaccine doses since program inception. During federal fiscal year 2019, 95% of arriving refugees had ≥1 documented measles-containing vaccine. The program's immunization schedule included eleven vaccines preventing fourteen diseases. In 2015-2019, only two vaccine preventable disease-associated refugee group travel cancellations occurred, compared to 2-8 cancellations annually prior to program initiation. To maintain uniform standards, dedicated staff and program-specific protocols for vaccination and monitoring were introduced. CONCLUSIONS: An overseas immunization program was successfully implemented for US-bound refugees. Due to reductions in refugee movement cancellation, lower cost of immunization overseas, and likely reductions in vaccine preventable disease-associated morbidity, we anticipate significant cost savings. Although maintaining uniform standards across diverse settings is challenging, solutions such as introduction of dedicated staff, protocol development, and ongoing technical support have ensured program cohesion, continuity, and advancement. Lessons learned can benefit similar programs implemented in the migration setting.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mitchell T, Dalal W, Klosovsky A, et al. An immunization program for US-bound refugees: Development, challenges, and opportunities 2012-present. Vaccine. 2020. PMID: 33218780. doi:10.1016/j.vaccine.2020.10.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。